Our Research Group
The Team
Maria Soledad Sosa
Principal Investigator
My undergraduate training consisted in the study of melanoma biology, in the laboratory of Osvaldo Podhajcer and under the direction of Dr. LLera at the renowned Leloir Institute, Buenos Aires, Argentina where I focused on the characterization of melanoma secretome using proteomics. From this training phase I published a very complete story in Proteomics (Sosa MS, et al., Proteomics 2007). My Ph.D. training program was carried out at the University of Pennsylvania in a joint program with the University of Buenos Aires. This training was under the mentorship of Dr. Marcelo Kazanietz, a well-recognized scientist in cell signaling studies in prostate and breast cancer. During this time I focused on the study of P-Rex1, a Rac-GEF protein, and how this factor contributed to the malignancy of mammary tumor cells. We demonstrated that P-Rex1 was important for migration and tumor development of breast cancer cells (Sosa MS, et al., Mol. Cell 2010). In 2010, I joined Dr. Julio Aguirre-Ghiso laboratory as a postdoc and worked on understanding how tumor cell dormancy is established once tumor cell disseminate to secondary organs. During my postdoc I was able to link the orphan nuclear receptor NR2F1 to a novel function during tumor cell dormancy (Sosa et.al. Nat. Com 2015). I found that NR2F1 was required for malignant cells to undergo dormancy by regulating retinoic acid signaling and cell cycle arrest in tumor cells. During my postdoc, I also worked in deciphering the mechanisms of dissemination from pre-malignant lesions (those formed even before a primary tumor is detected, such as ductal carcinoma in situ lesions) in breast cancer as a new source of disseminated cancer cells. This research project led to the publication of two paradigm-shifting papers in Nature in 2016 (Harper&Sosa, Nature, 2016, Hosseini et. al., Nature, 2016). At the beginning of 2017, I started my lab in the Department of Pharmacological Sciences at Icahn School of Medicine at Mount Sinai Hospital. I moved to Albert Einstein College of Medicine in the Department of Microbiology and Immunology at the beginning of 2023. Diversity Statement: I am aware that being a scientist in academia not only involves being successful in my research but also being a role model for the students and being able to exert my responsibilities to transform my community. Thus, I strive to improve racial diversity and gender equity in science. To this end, in 2021, I created the Commission of Diversity and Equity Support (CoDES), in the Department of Pharmacological Sciences (DPS) at Mount Sinai. The mission of this commission was to increase diversity and promote inclusion and equity by creating an inclusive culture based on mutual respect and to firmly oppose any form of discrimination. Our efforts impacted the DPS community evidenced by the following achievements: 1- an increase in the number of women speakers in our seminar series to 49%; 2- identification of three internal women faculty as candidates for our department, 3- introduction of DPS faculty to underrepresented high school students through lectures and courses organized by CEYE (Center of Excellence in Youth Education); 4- creation of recreational events to promote cultural diffusion. I have been involved in URM Ph.D/MD admission board, networking panels for women scientists, communicating my career path in local urban high schools, and teaching to minority black male young scientists through CEYE (Center of Excellence in Youth Education) . I have also participated in “Coffee chat series” organized by the Susan G. Komen Advocacy group and in the Susan G. Komen campaign for Spanish community together with “Telemundo Hoy Dia News”. This campaign aimed to reach the breast cancer Latin community by providing conversations in Spanish between a researcher and an advocate suffering from the disease. Currently, I am the Associate Director of the Diversity, Equity and Inclusion (DEI) office for the Montefiore Einstein Comprehensive Cancer Center (MECCC). I work closely with Women’s Initiative Network (WIN), and ExCEL program at Albert Einstein College of Medicine.
Carolina Rodriguez Tirado
Postdoctoral Fellow
Carolina did her PhD in Biomedical Sciences at the Albert Einstein College of Medicine and a two-year home-residency requirement in Chile as part of the Fulbright program that funded her studies. At Einstein, she worked under Dr. Jeffrey Pollard and Dr. Steven Porcelli describing polarizing factors that control macrophage roles during extravasation and metastasis of breast cancer. She was one of the first students to master the lung window technique for high resolution imaging of the living lungs in mouse models, a collaboration work with Dr. David Entenberg and Dr. John Condeelis. After that, she went back to Chile where she studied therapeutic strategies to mitigate radiation induced damage to normal tissue, specifically targeting microenvironmental signals derived from macrophages and mesenchymal stem cells. Then, she mediated an institutional agreement for research between the Universidad del Desarrollo in Chile and the University of Kansas in the US. In 2019, she decided to join my lab to continue shaping her career in the cancer field by studying the biology of disseminated cancer cells. In 2020, Carolina was awarded with a travel award from the prestigious European Association for Cancer Research (EACR) organization to present her work on early dissemination. In 2021, Carolina co-authored a paper published in the Journal of Experimental Metastasis on the discovery of a new agonist for NR2F1 to induce dormancy. In April 2022, Carolina published her first author paper from the lab in Cancer Research on the role of NR2F1 mediating dissemiantion of pre-malignant breast cancer cells.
Thoufiqul Alam Riaz
Associate
Thoufiqul received an undergraduate degree in pharmacy from Bangladesh. He is a creative and enthusiastic registered Pharmacist with over two years of experience in the pharmaceutical industry in Bangladesh. In early 2018, Thoufiqul was awarded Brain Korea-21 scholarship and joined Prof. Han-Jung Chae's laboratory, at JBNU, South Korea as a master’s student in the Department of Medical Science (Pharmacology). From two year’s tenure masters project, Thoufiqul developed his thesis where he showed the involvement of ER-localized enzyme PEMT in NAFLD-induced NASH progression during palmitic acid-treated ER stress conditions. Thoufiqul joined the lab in November 2022 as an Associate. Since then, he has been actively involved in a melanoma project previously developed by Nupura Kale and Alcina Rodrigues, two former technicians in the Sosa’s lab. The project focuses on understanding how melanoma cells regulate cellular dormancy once disseminated to distant sites. Thoufiqul contributions to this work have made substantial progress towards a mature shape of this manuscript in preparation.
Smrithi Jayashree Satheeshkumar
Research Trainee
Smrithi received her master in biochemistry in 2021 from the Department of Biochemistry, University of Kerala, India. Eager to broaden her expertise, she embarked on a transformative six-month training stint at the Translational Research Platform for Veterinary Biologicals (TRPVB), Tamil Nadu Veterinary and Animal Science University, India to gain experience in molecular and cell biology techniques and worked in detecting infectious diseases in animals. Driven by a passion for advancing scientific understanding in cancer and making tangible impacts, she then become a research assistant in cell biology at Tata Translational Cancer Research Centre (TTCRC) - TATA medical center, Kolkata, India. Here, she focused on gallbladder cancer and organoid development from patient-derived samples for developing personalized medicine. This endeavor held the promise of fostering personalized medicine approaches, a beacon of hope in the realm of oncological therapeutics. In November 2023, Smrithi embarked on a new chapter in her scientific journey as she joined Sosa’s lab, marking the beginning of her tenure as a research trainee. She is currently working on elucidating how transcriptional heterogeneity affects cellular dormancy during minimal residual disease in head and neck squamous cell carcinoma models.
Avalon Kelly
Medical student
Avalon is a current medical student at Albert Einstein College of Medicine. She pursued her undergraduate degree from Oregon State University in Biochemistry and Biophysics in 2021 and received an Undergraduate Research Fellow designation. In addition, she completed an honors thesis in the lab of Dr. Arup Indra in the College of Pharmacy with a project involving impaired epidermal homeostasis in neonatal mice with a heterozygous point mutation in the gene encoding for transcription factor Bcl11b. Through this project, she discovered her passion for investigating molecular mechanisms underlying the pathophysiology of disease. Before attending medical school, she received her EMT certification and worked as a medical scribe and medical assistant. Currently, Avalon is continuing to pursue research training and will be joining Sosa’s lab as a research fellow. She will work on elucidating how transcriptional heterogeneity affects the reawakening of dormant disseminated tumor cells during minimal residual disease.
Rusia Lee
Postdoctoral Fellow
Rusia received her masters’ degree in Cancer Biology from Drexel University. At Drexel, she developed her thesis work in the lab of Dr. Mauricio Reginato on the role of CDK5 in glioblastoma cell growth. She showed using RNAi and pharmacological inhibitors against CDK5 that CDK5 depletion blocks glioblastoma cell growth, proliferation, and tumor growth in vivo. In 2020, her contributions to the work were published in Oncogene. Rusia moved onto pursing a Ph.D. in Molecular, Cellular, and Developmental Biology at The Graduate Center, City University of New York (CUNY), where she worked under Dr. Jill Bargonetti. She identified a novel regulatory loop between the oncogenes MDM2 and MDMX and metastasis-promoting receptor, CXCR4. In 2021, Rusia was awarded the Temple U-Fox Chase/Hunter College (TUFCCC/HC) Regional Comprehensive Cancer Health Disparity Partnership (NCI U54) award of over $7,000 and won the Best Presentation Awards in 2022 and 2023. Rusia also won the Doctoral Student Research Travel Grant in 2022 to travel to AACR and the Cold Spring Harbor Metastasis Conference to present her work. Her first-author paper from this work is currently pending publication. In 2020, she contributed to a co-author publication on the E3 ligase activity of a MDM2 splice variant, MDM2-C and contributed to a publication in 2024 on the MDM2/MDMX-mtp53 recruitment of MDC1 and 53BP1 to chromatin in DNA repair pathways. In the Sosa lab, Rusia is currently studying the survival and dormancy mechanisms in early DCCs using the HER2+ breast cancer mouse model.
Nitisha Shrivastava
Staff Scientist
Dr. Nitisha Shrivastava obtained her master’s in Microbiology from India with recognition as a University topper (Gold medalist). She obtained her Ph. D in Radiation Biology from University of Delhi and Institute of Nuclear Medicine and Allied Sciences (DRDO) Delhi, India. In 2017, Nitisha did a short postdoc in Dr. Sosa’s lab at Mount Sinai Hospital, New York. Her work led to a co-authorship in the early dissemination story in Cancer Research, 2022 (Rodriguez Tirado et. al., Cancer Research, 2022). Then, she joined the laboratory of Dr. Ow at Albert Einstein College of Medicine where she focused on establishing the role of senescence to synergize radiation response and limit tumorigenesis in various, but not limited to head and neck cancer models. Then, Dr. Shrivastava joined Dr. Guha as a senior postdoc at Albert Einstein College of Medicine. Her work focused on utilizing radiation and ultrasound modalities in immortalized cell lines; organoids and animal models to understand and exploit the interplay between senescence and adaptive immune system with key focus on dendritic cells. Dr. Shrivastava has several publications in peer reviewed journals and international presentations underscoring her commitment to advancing the understanding of cancer mechanisms and therapeutic targets. Her work has also been recognized on various international and national forums since the beginning of her career, marking her excellence in the field. To name a few, Dr. Shrivastava has been awarded with the highly competitive and prestigious Scholar-in-training-Award by the American Association of Cancer Research (AACR), USA to recognize her as an outstanding young investigator. She has been winner of the proffered paper session in Head and Neck Society, NY, USA; awarded as an outstanding speaker for oral presentation in AECOM, NY, USA among several others. Dr. Shrivastava has recently joined Dr. Sosa lab. Her current interest in Sosa lab lies in understanding any overlapping similarities between senescence and dormancy of head and neck carcinomas to exploit therapeutic vulnerabilities to halt metastatic progression.